New clinical research offers a potential breakthrough for millions suffering from the persistent exhaustion associated with long COVID. A randomized clinical trial has found that fluvoxamine, a widely available and inexpensive antidepressant, may effectively mitigate the condition's most debilitating symptoms.
Clinical Trial Results
The study involved 399 adults struggling with long COVID fatigue. Participants were divided into groups receiving either fluvoxamine or a placebo. The results indicated that those treated with the medication experienced a significant reduction in fatigue levels and a measurable improvement in their overall quality of life.
A New Tool for Recovery
Fluvoxamine is now among the first medications to demonstrate meaningful clinical benefits for this specific condition. As long COVID continues to impact global health and workforce productivity, these findings provide a much-needed therapeutic lead for clinicians dealing with cases of chronic post-viral fatigue.
